期刊
SCIENTIFIC REPORTS
卷 7, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-09642-y
关键词
-
资金
- Royal Society Wolfson Research Merit Award
- TB Alliance
- European Union's 7th framework programme [261378]
- Medical Research Council [MR/K012118/1]
- Wellcome Trust [081569/Z/06/Z]
- Biotechnology and Biological Sciences Research Council [BB/N011945/1, 1112080] Funding Source: researchfish
- Medical Research Council [MR/K012118/1, MR/M501621/1, MR/L015080/1] Funding Source: researchfish
- BBSRC [BB/N011945/1] Funding Source: UKRI
- MRC [MR/L015080/1, MR/K012118/1] Funding Source: UKRI
Drug discovery efforts against the pathogen Mycobacterium tuberculosis (Mtb) have been advanced through phenotypic screens of extensive compound libraries. Such a screen revealed sulfolane 1 and indoline-5-sulfonamides 2 and 3 as potent inhibitors of mycobacterial growth. Optimization in the sulfolane series led to compound 4, which has proven activity in an in vivo murine model of Mtb infection. Here we identify the target and mode of inhibition of these compounds based on whole genome sequencing of spontaneous resistant mutants, which identified mutations locating to the essential alpha- and beta-subunits of tryptophan synthase. Over-expression studies confirmed tryptophan synthase as the biological target. Biochemical techniques probed the mechanism of inhibition, revealing the mutant enzyme complex incurs a fitness cost but does not prevent inhibitor binding. Mapping of the resistance conferring mutations onto a low-resolution crystal structure of Mtb tryptophan synthase showed they locate to the interface between the alpha- and beta-subunits. The discovery of anti-tubercular agents inhibiting tryptophan synthase highlights the therapeutic potential of this enzyme and draws attention to the prospect of other amino acid biosynthetic pathways as future Mtb drug targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据